133524-69-3

Basic information

• Product Name: N-Deboc-Docetaxel
• Synonyms: N-Deboc-Docetaxel;N-DesBoc Docetaxel;10-Desacetyl-N-debenzoylpaclitaxel;N-De(tert-butoxycarbonyl)-10-deacetyldocetaxel;N-Debenzoyl-10-deacetylpaclitaxel
• CAS NO: 133524-69-3
• Molecular Formula: C₃₈H₄₅NO₁₂
• Molecular Weight: 707.76
• Mol File: 133524-69-3.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 846.0±65.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 10.19±0.45(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: N-Deboc-Docetaxel(CAS DataBase Reference)
• NIST Chemistry Reference: N-Deboc-Docetaxel(133524-69-3)
• EPA Substance Registry System: N-Deboc-Docetaxel(133524-69-3)

Safety Data

• Hazardous Substances Data: 133524-69-3(Hazardous Substances Data)

Usage

Description

N-Deboc-Docetaxel is an impurity found in the synthesis of Docetaxel, a semisynthetic derivative of Paclitaxel. It is an antimitotic agent that promotes the assembly of microtubules and inhibits their depolymerization to free tubulin, making it a potential antineoplastic agent.

Uses

Used in Pharmaceutical Industry:
N-Deboc-Docetaxel is used as an impurity in the synthesis of Docetaxel for its antimitotic properties. It contributes to the development of Docetaxel, which is an antineoplastic agent used in the treatment of various types of cancer.

Upstream product

• 114915-20-7 Docetaxel 
• 95603-45-5 7,10-di(2,2,2-trichloroethyloxy-carbonyl)-13-cinnamoyl-10-deacetyl baccatin III 
• 157425-30-4 N-2,2,2-trichloroethoxycarbonyl phenylisoserine methyl ester 
• 143615-03-6 (4S,5R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid 
• 95603-44-4 7,10-di-(2,2,2-trichloroethyloxycarbonyl)-10-deacetylbaccatin III 
• 32981-86-5 10-deacetylbaccatin III 
• 196302-75-7 C₇₀H₇₁NO₁₉ 
• 881844-48-0 2-2-(2,4-dimethoxyphenyl)-3-(2-nitrobenzensulfenyl)-4⁽⁵⁾-phenyl-5(R)-oxazolidine carboxylic acid 10-deacetylbaccatin III 13-yl-ester 
• 202741-88-6 (4S,5R)-4-phenyl-2-trichloromethyl-1,3-oxazolidine-5-carboxylic acid 
• 124605-42-1 methyl (2R,3S)-3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionate 
• 342613-14-3 2'-O-(tert-butyldimethylsilyl)docetaxel 
• 195141-96-9 2'-(tert-butyldimethylsilyl)-7,10-di(triethylsilyl)docetaxel 
• 158810-74-3 (-)-(2R,3S)-methyl 3-(benzyloxycarbonylamino)-2-hydroxy-3-phenylpropanoate 
• 157240-36-3 (2R,3S)-3-phenylisoserine methyl ester 

Downstream Products

• 940867-25-4 d₉-docetaxel 
• 154044-50-5 N-de-tert-butoxycarbonyl-N-[2-(1,1,1-trifluoro-2-methyl)-propyloxycarbonyl]docetaxel 
• 1383561-40-7 d₉-docetaxel-2'-O-alaninate 
• 78432-77-6 10-deacetyltaxol 
• 114915-20-7 Docetaxel 
• 114915-20-7 C₄₃H₅₃NO₁₄ 
• 133524-71-7 C₄₃H₅₁NO₁₅ 

Relevant articles and documents

Design and synthesis of taxane derivatives of valproic acid as potent and selective cytotoxic agents

Resistance to anticancer agents has important implications for cancer chemotherapy. Small changes in chemical structures of cytotoxic agents can alter their biological interactions that can be beneficial in overcoming the drug resistance problem. Valproic acid, a well-known antiepileptic drug is in advanced clinical studies for cancer treatment. In the present study, valproic acid was incorporated into the taxane moiety at various positions and the new analogs were evaluated for their in vitro cytotoxicity. The novel analog, Valprotaxel showed comparable cytotoxicity in head and neck, and colon cancer cell lines with remarkable improvement in selectivity for cancer cells compared to paclitaxel and docetaxel.

Azoacetylenes for the Synthesis of Arylazotriazole Photoswitches

We report a modular approach toward novel arylazotriazole photoswitches and their photophysical characterization. Addition of lithiated TIPS-acetylene to aryldiazonium tetrafluoroborate salts gives a wide range of azoacetylenes, constituting an underexplored class of stable intermediates.In situdesilylation transiently leads to terminal arylazoacetylenes that undergo copper-catalyzed cycloadditions (CuAAC) with a diverse collection of organoazides. These include complex molecules derived from natural products or drugs, such as colchicine, taxol, tamiflu, and arachidonic acid. The arylazotriazoles display near-quantitative photoisomerization and long thermalZ-half-lives. Using the method, we introduce for the first time the design and synthesis of a diacetylene platform. It permits implementation of consecutive and diversity-oriented approaches linking two different conjugants to independently addressable acetylenes within a common photoswitchable azotriazole. This is showcased in the synthesis of several photoswitchable conjugates, with potential applications as photoPROTACs and biotin conjugates.

NOVEL TUNABLE PHOTOACTIVATABLE SILICON RHODAMINE FLUOROPHORES

The invention relates to a compound characterized by general formula (100), wherein R1 and R6 are H or F, R2, R3, R4 and R5 can be any substituent, R7, R8, RN1/s